Compare Amgen, Inc. (AMGN) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs EPAM Systems Inc — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while EPAM Systems Inc trades at $85.93 (market cap $4.38B). The key difference: Amgen, Inc. is far larger — about 44.8× EPAM Systems Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| AMGN | EPAM | |
|---|---|---|
Market Cap | $196.12B | $4.38B |
Sector | Health | Technology |
52-Week High | $388.16 | $221.40 |
52-Week Low | $271.18 | $76.04 |
Enterprise Value | $241.41B | $3.63B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
EPAM Systems trades at $83.89, down 3.9% in the last session, with a bearish technical signal from moving averages. The company maintains solid profitability with 29% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights EPAM's AI partnerships and upcoming Q2 2026 earnings release. Valuation metrics appear attractive with P/E of 12.05 and P/S of 0.84, well below sector averages.
The stock presents a compelling value opportunity with strong analyst support (65% buy ratings) and a $128.55 consensus price target representing 53% upside potential. Key risks include competitive pressures in IT services and recent net income margin compression from 9.61% in 2024 to 6.96% in 2025. The upcoming Q2 earnings report on July 6, 2026 will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
